Benitec Biopharma Inc.
For the period ended Sep 30, 2026. Filed Nov 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 13, 2026
BNTC$9.04-0.6%Stored close · as of Nov 13, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
Checking your notes…
(in thousands, except share and per share amounts)
| Three Months Ended | ||
|---|---|---|
| September 30, | ||
| 2026 | 2025 | |
| Operating expenses: | ||
| Research and development | 8,618 | 3,370 |
| General and administrative | 5,859 | 6,433 |
| Total operating expenses | 14,477 | 9,803 |
| Loss from operations | (14,477) | (9,803) |
| Other income (loss): | ||
| Foreign currency transaction gain (loss) | (23) | (89) |
| Interest income, net | 1,576 | 1,011 |
| Other expense, net | (1) | (84) |
| Total other income, net | 1,552 | 838 |
| Net loss | $(12,925) | $(8,965) |
| Other comprehensive income: | ||
| Unrealized foreign currency translation gain (loss) | 16 | 89 |
| Total other comprehensive income (loss) | 16 | 89 |
| Total comprehensive loss | $(12,909) | $(8,876) |
| Net loss | $(12,925) | $(8,965) |
| Net loss per share: | ||
| Basic and diluted | $(0.26) | $(0.22) |
| Weighted average number of shares outstanding: | ||
| Basic and diluted | 49,487,369 | 41,521,280 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.